Thyroid hormone, immunoglobin and complements for predicting hepatocellular carcinoma development in patients with hepatitis B virus-related liver cirrhosis

Table 1 Characteristics of patients with hepatitis B virus-related liver cirrhosis (training set)

Variables	Patients did not develope HCC (n = 123)	Patients developed HCC (n = 19)	Z or χ²	P value
Age (years)	50 (45, 61)	62 (55, 67)	3.622	< 0.01
Male	80 (65)	14 (73.7)	0.549	0.46
Decompensated cirrhosis	54 (43.9)	16 (84.2)	10.698	< 0.01
Diabetes	39 (31.7)	11 (57.9)	4.947	0.03
Alanine transaminase (U/L)	33 (21, 67)	28 (21, 53)	0.947	0.34
Aspartate transaminase (U/L)	33 (24, 54)	37 (27, 47)	0.258	0.80
Gamma-glutamyl transpeptidase (U/L)	56 (26, 82)	60 (26, 152)	0.665	0.51
Total bilirubin (µmol/L)	22.5 (15.7, 31.6)	24 (16.5, 28.4)	0.012	0.99
Albumin (g/L)	39.9 (32, 43.3)	40 (32.2, 44.9)	0.515	0.61
Creatinine (µmol/L)	77.3 (68.4, 89.9)	82.4 (69.1, 93.5)	0.809	0.42
International normalized ratio	1.1 (1.0, 1.3)	1.1 (1.0, 1.3)	0.254	0.80
Platelet (E+09/L)	99 (63, 145)	81 (56, 105)	1.840	0.07
Total triiodothyronine (nmol/L)	1.5 (1.2, 1.8)	1.4 (1.2, 1.6)	1.319	0.19
Total tetraiodothyronine (nmol/L)	112 (93.1, 127.8)	109.9 (95.5, 131.1)	0.088	0.93
Free triiodothyronine (pmol/L)	4.7 (4.1, 5.3)	4.6 (4.0, 5.2)	0.896	0.37
Free tetraiodothyronine (pmol/L)	11.3 (9.8, 12.5)	11.5 (9.1, 12.8)	0.084	0.93
Thyroid-stimulating hormone (μIU/mL)	1.5 (1.0, 2.0)	1.3 (0.9, 2.5)	0.285	0.78
Duration of follow-up (months)	33 (28, 38)	21 (14, 27)	4.825	< 0.01

Comparison was conducted by a Mann-Whitney U test (median and interquartile range) for continuous variables, and χ² test for categorial values. HCC: Hepatocellular carcinoma.